LEADER 00689nam0-22002651i-450- 001 990001229830403321 035 $a000122983 035 $aFED01000122983 035 $a(Aleph)000122983FED01 035 $a000122983 100 $a20000920d1964----km-y0itay50------ba 101 0 $aeng 200 1 $a<>study of arithmetic$fL. Clark Lay 210 $aNew York$cMacmillan$dc1964 610 0 $aAritmetica$aFondamenti 676 $a513.2 700 1$aLay,$bL. Clark$057023 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001229830403321 952 $a10-B-18$b6709$fMA1 959 $aMA1 996 $aStudy of arithmetic$9382030 997 $aUNINA DB $aING01 LEADER 02837nam 2200469z- 450 001 9910346745603321 005 20210212 035 $a(CKB)4920000000094258 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/58584 035 $a(oapen)doab58584 035 $a(EXLCZ)994920000000094258 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRole of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies 210 $cFrontiers Media SA$d2017 215 $a1 online resource (202 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-320-0 330 $aThis Research Topic was focused on provision of novel medical technologies worldwide keeping in mind financial sustainability challenge. An exemplary area certainly are oncology pharmaceuticals where prices have increased 10-fold in recent years leading to concerns on affordability. The objective of this collection of studies was to reveal some of the hidden underlying causes of unequal access to the medicines. Another core issue is the growing proportion of out-of-pocket health spending in many world regions. In line with the joint efforts of the editors and authors we received an exceptionally high response worldwide. This E-Book attracted a total of 37 self-standing research submissions out of which 32 ultimately passed external peer review and got published. Base affiliations of the authors spread across academia, pharmaceutical and medical device industry, governmental authorities and clinical medicine. Their home institutions were situated in fifteen different countries inclusive of Japan, Israel, Russia, USA, Germany, Italy, Netherlands, Austria, Spain, Malta, Serbia, Poland, Bulgaria, Hungary and Malaysia. We frankly believe that authors succeeded to cover important literature gaps referring to these world regions. We solicit global professional audience to put our efforts to the test and read this contribution to the health economics literature. 606 $aPharmacology$2bicssc 610 $acost 610 $aDecision Making 610 $aEmerging Markets 610 $aHealth Economics 610 $aHealth expenditure 610 $ahealth investment 610 $ahealth policy 610 $ahealth technology assessment 610 $amedical technology 610 $areimbursement 610 $aResource Allocation 615 7$aPharmacology 700 $aTetsuji Yamada$4auth$01329316 702 $aMihajlo (Michael) Jakovljevic$4auth 906 $aBOOK 912 $a9910346745603321 996 $aRole of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies$93039417 997 $aUNINA